Growing Use of Fluorine-18 for PET Imaging Drives Global Demand

Fluorine-18 (18F) is a fluorine radioisotope, a significant source of positrons. It is mostly produced with a cyclotron primarily by proton irradiation of a stable isotope of oxygen, 18O. Fluorine-18 is the most commonly used radioisotope in the positron emission tomography (PET) radiopharmaceuticals in clinical procedures. PET imaging has become a significant way to study physiological, biochemical, and pharmacological functions in humans. It is a non-invasive imaging technique that can measure the concentration of the tracer in tissues accurately due to its high sensitivity and high spatial resolution. Its physical and nuclear features, along with high distinct activity and ease of large-scale production, and thus the radiochemical labeling and molecular imaging seem more engaging. The significant increase in fluorine-18 radiotracers for PET imaging emphasizes the need for simplistic and efficient 18F-labeling procedures. Thus, the increasing need for PET imagining in healthcare sectors is driving the demand for the global fluorine-18 market during the forecast period.

In radiochemistry, the favorable nuclear and physical characteristics of fluorine-18, including high positron decay ratio, comparatively short half-life, and low positron energy have gained higher popularity in recent years. The global market has witnessed several radio synthetic methods generated for the embodiment of this radionuclide into biologically relevant and stimulating molecules ranging from drug-like molecules to antibodies and oligonucleotides, due to the nuclear properties and the ability to incorporate fluorine-18 in large quantities. Furthermore, fluorine-18 is being widely used in various applications in the field of oncology, neurology, and cardiology. The rise in the use of fluorine-18 in a variety of sectors is driving the global fluorine-18 market.

To know the scope of our report Get a Sample on Fluorine-18 Market

Decline in Overall PET/CT Scans during Coronavirus Crisis Hampers Demand for Fluorine-18

The COVID-19 pandemic has had a strong impact on almost every industry segment, including healthcare systems and diagnostic imaging services. As per the Radiological Society of North America, more than 40% to 90% decline in the medical imaging practices were recorded in 2020. The same slump has been recorded in various regions during the first wave of the pandemic. However, there was a limited study on the impact on the PET designated fluorine-18 market, which reported a slowdown in the demand for fluorine-18 during the first wave of coronavirus. The nuclear medicinal studies show a decrease in the number of PET-CT scans across the globe in the previous years and a halt in the growth rate during the first quarter of 2021. In the middle of the COVID-19 crisis, the number of ambulatories imaging decreased drastically, and optional imaging services were shut for a while. Besides, several regulations had to be updated in hospitals and radiology departments, regarding COVID-19 testing and PPE availability, and experts and managers had to be prepared to handle this new situation effectively.

In order to study the effects and infections of the COVID-19 virus, the fluorine-18 fluorodeoxyglucose PET-CT has been suggested as a non-invasive imaging method for detecting infectious or inflammatory diseases. The ability of 18F-FDG PET/CT to recognize sites of inflammation and infection is essentially related to the glycolytic activity of the cells involved in the inflammatory response. Thus, the producers of fluorine-18 for its medical applications are permitted to keep the production running with all the safety and precautionary measures to ensure the wellbeing of the workers. Furthermore, the rapid distribution of COVID-19 vaccines across various nations ensures the restoration of market and production in a short period. Moreover, the rising immediate demand for PET/CT scan and other fluorine-18 applications is anticipating growth of the fluorine-18 market during the forecast period.

Get a glimpse of the in-depth analysis through our Report Brochure

Expensive Setup Cost Likely to Hamper Fluorine-18 Market Growth

The positron emission tomography (PET) using fluorine-18 has been used with enhanced regularity in the care of patients with soft tissue sarcomas to predict the harmful potential of tumors, the diagnosis for survival, and response to chemotherapy. Imaging with PET has been proven to precisely detect primary tumors as well as lymph node and bone metastases in patients with sarcomas. In soft tissue sarcomas, changes in tumor fluorine-18-FDG uptake correlate significantly with the histopathological response, risk of tumor recurrence, and survival. Thus, PET using ([18] F-FDG) is emerging as a significant imaging modality in the administration of patients with soft tissue sarcomas. Moreover, FDG PET-CT is increasingly being used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience, which is contributing to the increasing demand for the fluorine-18 market.

Major factors driving the growth of the global fluorine-18 market include increase in the rate of cancer across the globe. The PET-CT test helps to diagnose cancer and provides more data, including whether a tumor is benign or malignant, and the response of cancer to treatment. However, the FDG-PET can be expensive and thus, lack availability. Moreover, the cost of installing the PET/CT scan facility with cyclotron is around US$ 5 Mn to US$ 6 Mn. These factors are limiting the expansion of the fluorine-18 market. Nevertheless, with advancements in research and technology and increase in demand for PET-CT imaging across the world, the manufacturers are now focusing on affordable setup measures. Thus, the fluorine-18 market is expecting a heavy demand from developing countries during the forecast period.

Asia Pacific to Invest More in Fluorine-18 Market

The global increase in the frequency and the prevalence of diseases such as cancer, Alzheimer’s, and cardiovascular diseases are generating demand for more precise diagnosis, driving the demand for F-18 isotopes. In addition, the high demand for cancer scan procedures in the developed countries is driving the FDG segment to dominate the global market during the forecast period. Moreover, the growing preference of individuals due to rising health awareness to perform PET/CT scans is one of the key factors propelling the market growth. Furthermore, Asia Pacific countries, including India and China are offering notable opportunities to F-18 producers, owing to the rise in the demand for use in health testing purposes. Hence, the global fluorine-18 market is projected to cross US$ 3 Bn by 2030, expanding at a CAGR of 7.5% from 2021 to 2031.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The future growth of the global fluorine-18 market can be credited to the rise in inclination toward diagnosis with radionuclides medicine, through PET-CT scan, as it is a well-established non-invasive imaging tool for studying disease development/progression. Moreover, PET-CT scans are proving conducive to evaluate cancer treatment more effectively. Therefore, an increasing number of doctors is preferring to carry out F18-based tests to check abnormalities of cancer cells, which offer significant opportunities for suppliers in the global market. However, the setup cost for the PET-CT system can be expensive for smaller sectors and regions. Thus, manufacturers are intensifying their use of materials to make devices more affordable. These will lead to the expansion of the fluorine-18 market in developing nations.

Fluorine-18 Market: Overview

  • Positron emission tomography, also called PET imaging or a PET scan, is a type of nuclear medicine imaging, which is primarily carried out through radioactive material. Nuclear medicine imaging uses small amounts of radioactive material to diagnose, evaluate, or treat diseases, and fluorine-18 is widely used in PET scan.
  • Fluorine-18 is the most widely used radioisotope in positron emission tomography (PET). It has a number of applications in the fields of oncology, neurology, and cardiology.
  • Combined PET/CT scanners outperform nearly all PET scans today. These combined scans help pinpoint abnormal metabolic activity and could provide more accurate diagnoses than the two scans performed separately. This is a major factor projected to drive the demand for fluorine-18.
  • Clinical applications of the positron emission tomography/computed tomography (PET-CT) with glucose analogue 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) are expanding beyond the area of oncology. Apart from its high usage in clinical oncology, FDG PET-CT is used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience. This boosts the growth the global fluorine-18 market.
  • Increase in incidence of cancer across the globe boosts the demand for PET-CT devices. PET-CT test helps to diagnose cancer and provides more information, including whether a tumor is benign or malignant, and how well the cancer is responding to treatment. PET-CT is an extremely sensitive imaging modality in the detection of malignant tissues and presents higher specificity than PET alone, which is the primary reason for fewer equivocal scans and better diagnostic results.

Market Segmentation: Fluorine-18 Market

  • In terms of product, the global fluorine-18 market has been classified into FDG, NaF, and others
  • Based on end user, the global fluorine-18 market has been divided into hospitals, diagnostic centers, and others
  • Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The fluorine-18 market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Fluorine-18 Market

  • In terms of region, the global fluorine-18 market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The U.S. held significant share of the fluorine-18 market in North America in 2019. The country is expected to retain market share during the forecast period. Robust healthcare infrastructure and quick adoption of advanced imaging equipment such as PET/CT are factors for the dominance of the U.S. fluorine-18 market.
  • Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and India, are projected to drive the fluorine-18 market in the region
  • The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the fluorine-18 market report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031.
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the fluorine-18 market and existing companies to increase market share and in the decision-making process

Major Fluorine-18 Market Players

  • The report concludes with the company profiles section that includes key information about the major players in the global fluorine-18 market
  • Leading players analyzed in the fluorine-18 market report are
    • Lantheus Holdings, Inc.
    • Siemens Healthineers
    • Advanced Accelerator Applications (a Novartis AG Company)
    • GE Healthcare (General Electric Company)
    • Blue Earth Diagnostics (A Bracco Imaging Company)
    • Jubilant Pharma Limited
    • China lsotope & Radiation Corporation
    • Eli Lilly and Company
    • Curium Pharma
    • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Each of these players has been profiled in the fluorine-18 market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Fluorine-18 Market – Segmentation

TMR’s study on the global fluorine-18 market includes information divided into three segments: product, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global fluorine-18 market have been discussed in detail.

Product
  • FDG
  • NaF
  • Others
End User
  • Hospitals
  • Diagnostic Centers
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Fluorine-18 market was valued over US$ 1.5 Bn in 2020 and to exceed valuation of US$ 3 Bn by 2031

Fluorine-18 market is projected to expand at a CAGR of 7.5% from 2021 to 2031

Fluorine-18 market is driven by increasing need for PET imagining in healthcare sectors and increase in the rate of cancer across the globe

The FDG segment is expected to account for a major share of the global fluorine-18 market by 2031, due to the increase in demand for PET/CT scan in oncology

Key players in the global fluorine-18 market include Lantheus Holdings, Inc., Siemens Healthineers, Advanced Accelerator Applications (a Novartis AG Company), GE Healthcare (General Electric Company), Blue Earth Diagnostics (A Bracco Imaging Company)

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fluorine-18 Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities 

    4.3. Global Fluorine-18 Market Analysis and Forecast, 2017–2031

5. Market Outlook 

    5.1. Radioactive Material Transport Guidelines 

    5.2. Radiation Protection Guidelines 

    5.3. Operating Cost and Pricing Analysis- PET/CT Scan and Fluorine-18 Dose

    5.4. Number of PET/CT Scan Installed 

    5.5. COVID-19 Impact Analysis 

    5.6. Number of Radiotherapy Centers, by Major Countries 

    5.7. Pricing Analysis, by Major Brands

    5.8. PET Tracers Clinical Trails

6. Global Fluorine-18 Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        6.2.1. FDG

        6.2.2. NaF

        6.2.3. Others

    6.3. Global Fluorine-18 Market Attractiveness Analysis, by Product 

7. Global Fluorine-18 Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        7.2.1. Hospitals

        7.2.2. Diagnostic Centers

        7.2.3. Others

    7.3. Global Fluorine-18 Market Attractiveness Analysis, by End-user

8. Global Fluorine-18 Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Fluorine-18 Market Attractiveness Analysis, by Region

9. North America Fluorine-18 Market Analysis and Forecast

    9.1. Introduction 

    9.2. North America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        9.2.1. FDG

        9.2.2. NaF

        9.2.3. Others

    9.3. North America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        9.3.1. Hospitals

        9.3.2. Diagnostic Centers

        9.3.3. Others 

    9.4. North America Fluorine-18 Market Value (US$ Mn) Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Fluorine-18 Market Attractiveness Analysis

        9.5.1. By Product 

        9.5.2. By End-user

        9.5.3. By Country 

10. Europe Fluorine-18 Market Analysis and Forecast

    10.1. Introduction 

    10.2. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        10.2.1. FDG

        10.2.2. NaF

        10.2.3. Others

    10.3. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        10.3.1. Hospitals

        10.3.2. Diagnostic Centers

        10.3.3. Others

    10.4. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Fluorine-18 Market Attractiveness Analysis

        10.5.1. By Product 

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Fluorine-18 Market Analysis and Forecast

    11.1. Introduction 

    11.2. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        11.2.1. FDG

        11.2.2. NaF

        11.2.3. Others

    11.3. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        11.3.1. Hospitals

        11.3.2. Diagnostic Centers

        11.3.3. Others

    11.4. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Fluorine-18 Market Attractiveness Analysis

        11.5.1. By Product 

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Fluorine-18 Market Analysis and Forecast

    12.1. Introduction 

    12.2. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        12.2.1. FDG

        12.2.2. NaF

        12.2.3. Others

    12.3. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        12.3.1. Hospitals

        12.3.2. Diagnostic Centers

        12.3.3. Others

    12.4. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Fluorine-18 Market Attractiveness Analysis

        12.5.1. By Product 

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Fluorine-18 Market Analysis and Forecast

    13.1. Introduction 

    13.2. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

        13.2.1. FDG

        13.2.2. NaF

        13.2.3. Others

    13.3. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        13.3.1. Hospitals

        13.3.2. Diagnostic Centers

        13.3.3. Others

    13.4. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Fluorine-18 Market Attractiveness Analysis

        13.5.1. By Product 

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Position Analysis, by Company, 2019

    14.2. Company Profiles

        14.2.1. Lantheus Holdings, Inc.

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Growth Strategies

            14.2.1.3. SWOT Analysis

        14.2.2. Siemens Healthineers

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Growth Strategies

            14.2.2.3. SWOT Analysis

        14.2.3. Advanced Accelerator Applications (a Novartis AG Company)

            14.2.3.1. Company Overview (HQ, Business Segments)

            14.2.3.2. Growth Strategies

            14.2.3.3. SWOT Analysis

        14.2.4. GE Healthcare

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Growth Strategies

            14.2.4.3. SWOT Analysis

        14.2.5. Blue Earth Diagnostics (A Bracco Imaging Company)

            14.2.5.1. Company Overview (HQ, Business Segments)

            14.2.5.2. Growth Strategies

            14.2.5.3. SWOT Analysis

        14.2.6. Jubilant Pharma Limited

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.6.2. Growth Strategies

            14.2.6.3. SWOT Analysis

        14.2.7. China lsotope & Radiation Corporation

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.7.2. Growth Strategies

            14.2.7.3. SWOT Analysis

        14.2.8. Eli Lilly and Company

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Growth Strategies

            14.2.8.3. SWOT Analysis

        14.2.9. Curium Pharma

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.9.2. Growth Strategies

            14.2.9.3. SWOT Analysis

        14.2.10. Yantai Dongcheng Pharmaceutical Group Co., Ltd.

            14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.10.2. Growth Strategies

            14.2.10.3. SWOT Analysis

List of Tables

Table 01: North America Installed Base

Table 02: Europe Installed Base

Table 03: Europe Installed Base

Table 04: Asia Pacific and RoW Installed Base 

Table 05: Number of Radiotherapy Centers, by Country

Table 06: PET tracers in clinical trials

Table 07: PET tracers in clinical trials

Table 08: PET tracers in clinical trials

Table 09: PET tracers in clinical trials

Table 10: PET tracers in clinical trials

Table 11: PET tracers in clinical trials

Table 12: PET tracers in clinical trials

Table 13: PET tracers in clinical trials

Table 14: Global Fluorine-18 Market Revenue (US$ Mn) Forecast, by Product, 2017–2031

Table 15: Global Fluorine-18 Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Global Fluorine-18 Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 17: North America Fluorine-18 Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 18: North America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 19: North America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 22: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 23: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 24: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 25: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 28: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 29: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 30: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 31: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Fluorine-18 Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global Fluorine-18 Market Value Share, by Region, 2020

Figure 03: Global Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 04: Global Fluorine-18 Market Revenue (US$ Mn), by FDG, 2017–2031

Figure 05: Global Fluorine-18 Market Revenue (US$ Mn), by NaF, 2017–2031

Figure 06: Global Fluorine-18 Market Revenue (US$ Mn), by Others, 2017–2031

Figure 07: Global Fluorine-18 Market Attractive Analysis, by Product, 2021–2031

Figure 08: Global Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 09: Global Fluorine-18 Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 10: Global Fluorine-18 Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

Figure 11: Global Fluorine-18 Market Revenue (US$ Mn), by Others, 2017–2031

Figure 12: Global Fluorine-18 Market Attractive Analysis, by End-user, 2021–2031

Figure 13: Global Fluorine-18 Market Value Share Analysis, by Region, 2020 and 2031

Figure 14: Global Fluorine-18 Market Attractiveness Analysis, by Region, 2021–2031

Figure 15: North America Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031

Figure 16: North America Fluorine-18 Market Value Share Analysis, by Country, 2020 and 2031

Figure 17: North America Fluorine-18 Market Attractiveness Analysis, by Country, 2021–2031

Figure 18: North America Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 19: North America Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031

Figure 20: North America Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 21: North America Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031

Figure 22: Europe Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031

Figure 23: Europe Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 24: Europe Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 25: Europe Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 26: Europe Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031

Figure 27: Europe Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 28: Europe Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031

Figure 29: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031

Figure 30: Asia Pacific Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 31: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 32: Asia Pacific Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 33: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031

Figure 34: Asia Pacific Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 35: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031

Figure 36: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Latin America Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 38: Latin America Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 39: Latin America Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 40: Latin America Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031

Figure 41: Latin America Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 42: Latin America Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031

Figure 43: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031

Figure 44: Middle East & Africa Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 45: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 46: Middle East & Africa Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031

Figure 47: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031

Figure 48: Middle East & Africa Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031

Figure 49: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031

Figure 50: Fluorine 18-Market Ranking Analysis

Figure 51: Siemens Healthineers AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 52: Siemens Healthineers AG Breakdown of Net Sales (%), by Region, 2020

Figure 53: Siemens Healthineers AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 54: Siemens Healthineers AG Breakdown of Net Sales (%), by Business Segment, 2020

Figure 55: Lantheus Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 56: Lantheus Holdings, Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 57: Lantheus Holdings, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 58: Jubilant Pharma Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 59: Jubilant Pharma Limited Breakdown of Net Sales (%), by Region/Country, 2020

Figure 60: Jubilant Pharma Limited Breakdown of Net Sales (%), by Business Segment, 2020

Figure 61: Jubilant Pharma Limited Breakdown of Net Sales (%), by Specialty Pharmaceuticals, 2020

Figure 62: China lsotope & Radiation Corporation - Revenue (US$ Mn) and Y-o-Y Growth (%), 2019–2020

Figure 63: China lsotope & Radiation Corporation - Breakdown of Net Sales (%), by Business Segment, 2020

Figure 64: GE Healthcare Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 65: GE Healthcare Breakdown of Net Sales (%), by Region/Country, 2020

Figure 66: GE Healthcare Breakdown of Net Sales (%), by Business Segment, 2020

Figure 67: GE Healthcare R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 68: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 69: Eli Lilly and Company R&D Intensity - Company Level, 2018–2020

Figure 70: Eli Lilly and Company Breakdown of Net Sales, by Region, 2020

Figure 71: Eli Lilly and Company Breakdown of Net Sales, by Therapeutic Area, 2020

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization